REVIEW PAPER
Changing views toward mRNA based covid vaccines in the scientific literature: 2020–2024
More details
Hide details
1
Department of Medical Biology, School of Public Health, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Poland
Submission date: 2024-05-30
Final revision date: 2024-06-11
Acceptance date: 2024-06-12
Online publication date: 2024-07-16
Corresponding author
Michael Allen Thoene
Department of Medical Biology, School of Public Health, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Żołnierska 14C, 10-561 Olsztyn, Poland
Pol. Ann. Med. 2024;31(2):152-157
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Before the global Covid-19 pandemic caused by the SARS-CoV-2 virus, mRNA based vaccines had never been administered to the public outside of a single clinical trial that was not completed at the time. However, within the space of 9 months these experimental vaccines were administered to millions through an emergency use authorization (EUA).
Aim:
The aim of this article is to raise awareness that medical science can be biased due to social and economic influences, especially during high stress epochs in history. Scientists should be conscious of always being objective and skeptical regardless of what is happening in the wider world.
Material and methods:
A literature survey was performed examining the reporting of severe adverse events (SAEs) in articles published between 2020 and 2024.
Results and discussion:
From 2020 to 2024, the literature has gone from claiming there are absolutely no SAEs from mRNA based vaccines (2020/2021) to an acknowledgment of a significant number of various SAEs (2023/2024); including but not limited to neurological complications, myocarditis, pericarditis and thrombosis.
Conclusions:
The early scientific literature was biased, so as not to report SAEs, due to social and political concerns and overwhelming corporate greed. Only in the last year have scientists been able to publish articles that acknowledge a high number of SAEs linked to mRNA based vaccines. This should act as a warning that science should be completely objective when evaluating health risks, but can often be influenced by social and economic considerations.
FUNDING
This study received no outside funding.
CONFLICT OF INTEREST
The author has no conflicts of interest to declare.
REFERENCES (32)
1.
Lin Y, Hu Z, Zhao Q, Alias H, Danaee M, Wong LP. Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China. PLoS Negl Trop Dis. 2020;14(12):e0008961.
https://doi.org/10.1371/journa....
2.
Bok K, Sitar S, Graham BS, Mascola JR. Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. Immunity. 2021;54(8):1636–1651.
https://doi.org/10.1016/j.immu....
4.
Pokharkar D, Sawale G, Bandarkar A, Galande R, Patil K. A review on vaccines against various diseases. World J Pharm Res. 2021;10(10):291–306. doi: 10.20959/wjpps202110-21179.
6.
Faksova K, Walsh D, Jiang Y, et al. COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals. Vaccine. 2024;42(9):2200–2211.
https://doi.org/10.1016/j.vacc....
7.
Kim DH, Kim JH, Oh IS, Choe YJ, Choe SA, Shin JY. Adverse Events Following COVID-19 Vaccination in Adolescents: Insights From Pharmacovigilance Study of VigiBase. J Korean Med Sci. 2024;39(8):e76.
https://doi.org/10.3346/jkms.2....
8.
Yasmin F, Najeeb H, Naeem U, et al. Adverse events following COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia. Immun Inflamm Dis. 2023;11(3):e807.
https://doi.org/10.1002/iid3.8....
9.
Tsang RS, Agrawal U, Joy M, et al. Adverse events after first and second doses of COVID-19 vaccination in England: a national vaccine surveillance platform self-controlled case series study. J R Soc Med. 2024;117(4):134–148.
https://doi.org/10.1177/014107....
10.
Bitounis D, Jacquinet E, Rogers MA, Amiji MM. Strategies to reduce the risks of mRNA drug and vaccine toxicity. Nat Rev Drug Discov. 2024;23(4):281–300.
https://doi.org/10.1038/s41573....
11.
Harris DA, Hayes KN, Zullo AR, et al. Comparative Risks of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Older US Adults. JAMA Netw Open. 2023;6(8):e2326852.
https://doi.org/10.1001/jamane....
13.
Mead MN, Seneff S, Wolfinger R, et al. COVID-19 mRNA Vaccines: Lessons Learned from the Registrational Trials and Global Vaccination Campaign. Cureus. 2024;16(1):e52876.
https://doi.org/10.7759/cureus....
14.
Fraiman J, Erviti J, Jones M, et al. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. Vaccine. 2022;40(40):5798–5805.
https://doi.org/10.1016/j.vacc....
17.
Shafiq A, Salameh MA, Laswi I, et al. Neurological Immune-Related Adverse Events After COVID-19 Vaccination: A Systematic Review. J Clin Pharmacol. 2022;62(3):291–303.
https://doi.org/10.1002/jcph.2....
18.
Hana D, Patel K, Roman S, Gattas B, Sofka S. Clinical Cardiovascular Adverse Events Reported Post-COVID-19 Vaccination: Are They a Real Risk? Curr Probl Cardiol. 2022;47(3):101077.
https://doi.org/10.1016/j.cpca....
20.
Iba T, Levy JH. Thrombosis and thrombocytopenia in COVID-19 and after COVID-19 vaccination. Trends Cardiovasc Med. 2022;32(5):249–256.
https://doi.org/10.1016/j.tcm.....
21.
Kouhpayeh H, Ansari H. Adverse events following COVID-19 vaccination: A systematic review and meta-analysis. Int Immunopharmacol. 2022;109:108906.
https://doi.org/10.1016/j.inti....
22.
Ioannidis JPA, Axfors C, Contopoulos-Ioannidis DG. Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters. Environ Res. 2020;188:109890.
https://doi.org/10.1016/j.envr....
23.
Roy S, Mukhopadhyay S, Mukherjee S, Samajdar SS, Tripathi SK. In search of protective antibody for coronavirus disease 2019: A retrospective study. Pol Ann Med. 2022;29(2):189–195.
https://doi.org/10.29089/paom/....
24.
Mahroum N, Lavine N, Ohayon A, et al. COVID-19 Vaccination and the Rate of Immune and Autoimmune Adverse Events Following Immunization: Insights From a Narrative Literature Review. Front Immunol. 2022;13:872683.
https://doi.org/10.3389/fimmu.....
25.
Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect. 2022;28(2):202–221.
https://doi.org/10.1016/j.cmi.....
26.
Bardenheier BH, Gravenstein S, Blackman C, et al. Adverse Events Following One Dose of mRNA COVID-19 Vaccination Among US Nursing Home Residents With and Without a Previous SARS-CoV-2 Infection. J Am Med Dir Assoc. 2021;22(11):2228–2232.
https://doi.org/10.1016/j.jamd....
27.
Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403–416.
https://doi.org/10.1056/NEJMoa....
28.
Liu Q, Qin C, Liu M, Liu J. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. Infect Dis Poverty. 2021;10(1):132.
https://doi.org/10.1186/s40249....
29.
Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020;383(20):1920–1931.
https://doi.org/10.1056/NEJMoa....
30.
Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med. 2021; 385(12):1078–1090.
https://doi.org/10.1056/NEJMoa....
31.
Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27):2603–2615.
https://doi.org/10.1056/NEJMoa....
32.
Thomas SJ, Moreira ED Jr, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. 2021;385(19):1761–1773.
https://doi.org/10.1056/NEJMoa....